Beam Therapeutics is focused on developing precision genetic medicines using base editing technologies.

Beam Therapeutics

Beam Therapeutics | 66,012 followers on LinkedIn. Our vision is to provide life-long cures for patients suffering from serious diseases. | Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes.

Executive Assistant

Jocelyn Mortero

Licensed Patent Attorney with twenty years of experience in the life sciences

William Schmidt

Nada Martini

Sr. Director, EHS at Beam Therapeutics

Mandy Stone

Curious how base editing works? Check out our animation and learn how the #BeamTeam is tackling diseases one letter at a time! #DaretoBeam

Today, the #BeamTeam ’s John Evans joined the #ASAPBioPharma Conference as the Keynote and shared Beam’s approach to gene editing and discussed how strategic partnerships are critical to advancing and expanding patient options to support them living their best lives. Thank you, Association of Strategic Alliance Professionals for hosting the #BeamTeam ! #DaretoBeam

Today, Beam Therapeutics announced the acceptance of multiple oral and poster presentations, including the first clinical data from a Beam program, at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition, taking place December 7-10, 2024, in San Diego. Full press release here: https://lnkd.in/eBy7_ekU #DaretoBeam

Today, Beam Therapeutics reported third quarter 2024 financial results and provided updates across the company’s hematology and genetic disease franchises. Full details here: https://lnkd.in/eZcxiw-K Reminder: Beam will host a conference call today, November 5, 2024, at 8:30 a.m. ET. To join the conference call, visit the link in the press release #DaretoBeam

The #BeamTeam recently participated in The Leukemia & Lymphoma Society 's Light The Night in Boston and North Carolina. Thank you to everyone who walked in support of, to celebrate, honor, and remember those touched by blood cancers. #LightTheNight #DaretoBeam

Beam will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company’s abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH). A live webcast of the presentation will be available here: https://lnkd.in/eruR6iPf and under "Events & Presentations" in the Investors section of Beam's website at www.beamtx.com .

Our Clinical Operations Team is growing and looking for an experienced Senior Clinical Trial Manager! This role must fully understand and lead the cross-functional team through all day-to-day activities within the clinical trial life cycle. These day-to-day activities include managing all trial start-up, conduct and close-out activities to both industry and corporate standards within ICH/GCP Guidelines. Learn more here #DaretoBeam : https://lnkd.in/e29w5nAx

Beam is looking for highly energetic and curious Co-ops across multiple departments to join the #BeamTeam ! Check out our Co-op opportunities here: https://lnkd.in/eduTfpdQ #DaretoBeam

Recently, the #BeamTeam celebrated the end of summer and start of fall in NC and MA! Thank you to the entire Beam Team for the hard work and dedication to our vision and each other! #TallShipBoston

Throughout September, the #BeamTeam in MA and NC participated in #Alpha1RidingforaReason to raise awareness of Alpha 1 antitrypsin deficiency and its impact on affected families. #Alpha1

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

COM:BEAMTX

Beam Therapeutics

Last Close

23.58

22/11 21:00

Market Cap

1.97B

Beta: -

Volume Today

1.16M

Avg: -

Filings Not Available